Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01518374 · ClinicalTrials.gov registry record · Phase 2
Clinical Evaluation of Florbetapir F 18 (18F-AV-45)
A Phase 2 study, sponsored by Avid Radiopharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,768
- Enrollment target
NCT01518374: Completed Phase 2 study, sponsored by Avid Radiopharmaceuticals.
NCT01518374 is a Phase 2 study that has completed, run by Avid Radiopharmaceuticals. The registered enrollment target is 1,768 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1229% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01518374, a Phase 2 study, has completed, sponsored by Avid Radiopharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,768 participants
- Enrollment target
Study Summary
This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.
Primary Outcome
Frequency of treatment-emergent adverse events considered related to florbetapir administration by the study investigator. Related events with a frequency \> 0.2% are reported. (note: all treatment-emergent adverse events, regardless of relatedness designation, are reported in "Adverse Events" section below)
Interventions
- DRUG Florbetapir F 18
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,768 participants |
| Start Date | 2009-12 |
| Est. Completion | 2017-05-03 |
| Phase | Phase 2 |
What the finished NCT01518374 record still lists
NCT01518374 is an interventional study that assigns participants to a tested intervention. Its 1,768 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (1229% higher).
The record links to 0 conditions, and to 1 intervention - of which Florbetapir F 18 is the first listed.
NCT01518374 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01518374 about?
NCT01518374 is a clinical study titled "Clinical Evaluation of Florbetapir F 18 (18F-AV-45)". This protocol is designed to standardize imaging studies using florbetapir F 18 PET to provide information on amyloid burden in subjects participating in other studies (companion protocol) such as longitudinal studies of aging and studies of biomarkers for neurodegenerative diseases.
What is the current status of trial NCT01518374?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,768 participants. The study started on 2009-12. Estimated completion is 2017-05-03.
What interventions are being tested in trial NCT01518374?
The interventions under investigation include: Florbetapir F 18 (DRUG).
Who is sponsoring clinical trial NCT01518374?
This trial is sponsored by Avid Radiopharmaceuticals, which has 42 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01518374's enrollment target sits among peer trials
1,768 11th of 2000 higher than 1,990 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06239688 · 1,764 participants · NA
Evaluating a National Person-Centered Training Program to Strengthen the Dementia Care Workforce
- NCT03067181 · 1,780 participants · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
- NCT06526650 · 1,780 participants · NA
'Ai Pono Cooking Demonstrations
- NCT06872892 · 1,755 participants · Phase 3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia